During the past medical school year, I had the privilege to be present as our pediatric neurology team helped administer the first drug approved by the FDA to treat the underlaying cause of Duchenne Muscular Dystrophy. Because of my vested personal interests in DMD, I wrote a brief editorial in Pediatric Neurology, highlighting the momentous occasion that was worth celebrating. Much work certainly still needs to be done, but for a brief moment, this was worth celebrating.
In contribution to our overall grant, our most recent publication, led by Dr. Parvesh Sharma and myself, investigates the development of biocompatible nanoparticles, capable of imaging damaged murine muscle. Methodically, we've developed biocompatible nanoparticles that are able to be associated with Indocyanine Green (ICG), which are passively taken up into damage mouse muscle. Importantly, the particles protect the optical fluorescent properties of the ICG, allowing for imaging long after administration compared to raw ICG. These developments lay the exciting groundwork for developing a safe, longitudinal, reliable, and inexpensive way to optically image damaged and dystrophic muscle.
I'm a current MD-PhD candidate, working hard to help treat and manage muscular dystrophies